TP53 and ovarian cancer: The 5‐year OS for drug‐resistant recurrent ovarian cancer patients (44 ± 11.07 months, 95% CI: 231.24–53.66 months) was significantly lower than that of drug‐sensitive recurrent ovarian cancer patients (58 ± 3.97 months; 95% CI: 50.05–65.59 months; p = 0.024) TP53 was the most frequently mutated gene in both drug‐resistant (9/10, 90%) and drug‐sensitive recurrent ovarian cancers (10/11, 91%).